Presentation is loading. Please wait.

Presentation is loading. Please wait.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,

Similar presentations


Presentation on theme: "Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,"— Presentation transcript:

1 Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, Manuela Ceccarelli, Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonello Pinto, Sara Galimberti, Alessia Bari, Delia Rota-Scalabrini, Angela Ferrari, Francesco Zaja, Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi, Enrica Gamba, Andrea Evangelista, and Umberto Vitolo Blood Volume 122(23): November 28, 2013 ©2013 by American Society of Hematology

2 Study plan for MRD analysis. Marco Ladetto et al. Blood 2013;122: ©2013 by American Society of Hematology

3 Descriptive results of bcl-2/IgH PCR analysis. Marco Ladetto et al. Blood 2013;122: ©2013 by American Society of Hematology

4 Time-varying covariate model of accumulation of PCR-negative findings. Marco Ladetto et al. Blood 2013;122: ©2013 by American Society of Hematology

5 Effect of MRD by response status and treatment group. Marco Ladetto et al. Blood 2013;122: ©2013 by American Society of Hematology


Download ppt "Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,"

Similar presentations


Ads by Google